With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine.

With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.

Biotechnology

Education

Tune Therapeutics

Charles A. Gersbach

Jason Dean

Kendra Congdon

Tyler Goodwin

Zachary Hale

Georgeta Puscalau

Katherine H.

Michael P. Hefferan

Derek Jantz

Christina Jordan

Glenn Murphy

Luis Sanchez-Perez

Shannon Grace

Ryan Tam

The Leadership Team at Tune Therapeutics is responsible for setting the strategic direction and vision of the company, steering its innovative research and development initiatives, and optimizing operational efficiencies. Comprising experienced co-founders and executives, the team drives the advancement of the TEMPO epigenomic control platform, fosters collaboration across departments, and ensures alignment with long-term goals to transform genetic medicine and tackle complex diseases.

Leadership Team

Research and Development

Technical Operations and Engineering

Leadership Team

About

Team members

Other teams at Tune Therapeutics

Research and Development

Technical Operations and Engineering